Adults 65 years and older may qualify for a study evaluating an investigational vaccine designed to help prevent C. difficile (C. diff) infection.
Adults 65 years and older may qualify for a study evaluating an investigational vaccine designed to help prevent C. difficile (C. diff) infection.
C. difficile (C. diff) is a bacterium that can cause infection of the large intestine, leading to symptoms ranging from diarrhea to severe, life-threatening complications. These infections are more common in older adults, especially those who have recently used antibiotics or had hospital stays.
Researchers are working to develop vaccines that may help prevent C. diff infections before they occur. This study is evaluating an investigational vaccine to better understand its safety, tolerability, and how well it may help protect against C. diff infection.
Participants in this study will receive either the investigational C. diff vaccine or a placebo (an inactive substance that looks like the vaccine but does not contain active ingredients). There is a 50% chance of receiving placebo.
Participation in the study will last approximately 3.5 years and includes scheduled clinic visits, telephone check-ins, and regular follow-up.
You may be able to join if you:
Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating […]
Rochester Clinical Research is seeking adults to participate in a research study evaluating an investigational medication for nerve pain caused […]
Adults 65 years and older may qualify for a study evaluating an investigational vaccine designed to help prevent C. difficile […]
Rochester Clinical Research is enrolling healthy adults ages 50–64 for a COVID-19 vaccine research study (non-mRNA). This study is enrolling […]
Rochester Clinical Research is currently enrolling adults for a research study evaluating a once-weekly injection for people with knee pain […]
Adults 18 to 80 years of age may qualify for a study evaluating an investigational treatment for irritable bowel syndrome […]